Last reviewed · How we verify
HSK16149
At a glance
| Generic name | HSK16149 |
|---|---|
| Also known as | HSK16149（phase 1）, HSK16149 |
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder (PHASE2)
- To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia (PHASE3)
- Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin (PHASE2)
- Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China (PHASE3)
- The Drug-drug Interaction of HSK16149 Capsule With Probenecid Tablets or Cimetidine Tablets in Healthy Subjects (PHASE1)
- To Evaluate the Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Herpetic Neuralgia (PHASE2)
- To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in China (NA)
- HSK16149 for Perioperative Analgesia in Orthopedic Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK16149 CI brief — competitive landscape report
- HSK16149 updates RSS · CI watch RSS
- Haisco Pharmaceutical Group Co., Ltd. portfolio CI